These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 32745811)

  • 21. Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants.
    McCallum M; Walls AC; Sprouse KR; Bowen JE; Rosen LE; Dang HV; De Marco A; Franko N; Tilles SW; Logue J; Miranda MC; Ahlrichs M; Carter L; Snell G; Pizzuto MS; Chu HY; Van Voorhis WC; Corti D; Veesler D
    Science; 2021 Dec; 374(6575):1621-1626. PubMed ID: 34751595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deposition distribution of the new coronavirus (SARS-CoV-2) in the human airways upon exposure to cough-generated droplets and aerosol particles.
    Madas BG; Füri P; Farkas Á; Nagy A; Czitrovszky A; Balásházy I; Schay GG; Horváth A
    Sci Rep; 2020 Dec; 10(1):22430. PubMed ID: 33384436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Possible inhibition of GM-CSF production by SARS-CoV-2 spike-based vaccines.
    Li J; Wang P; Tracey KJ; Wang H
    Mol Med; 2021 May; 27(1):49. PubMed ID: 34022793
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies.
    Hussain A; Hasan A; Nejadi Babadaei MM; Bloukh SH; Chowdhury MEH; Sharifi M; Haghighat S; Falahati M
    Biomed Pharmacother; 2020 Oct; 130():110559. PubMed ID: 32768882
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Origin and genomic characteristics of SARS-CoV-2 and its interaction with angiotensin converting enzyme type 2 receptors, focusing on the gastrointestinal tract.
    Galanopoulos M; Doukatas A; Gazouli M
    World J Gastroenterol; 2020 Nov; 26(41):6335-6345. PubMed ID: 33244196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern
    Chiem K; Morales Vasquez D; Silvas JA; Park JG; Piepenbrink MS; Sourimant J; Lin MJ; Greninger AL; Plemper RK; Torrelles JB; Walter MR; de la Torre JC; Kobie JK; Ye C; Martinez-Sobrido L
    J Virol; 2021 Oct; 95(22):e0112621. PubMed ID: 34495697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SARS-CoV-2: Targeted managements and vaccine development.
    Bakhiet M; Taurin S
    Cytokine Growth Factor Rev; 2021 Apr; 58():16-29. PubMed ID: 33293238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. COVID-19 Infection: Targeting Possibilities for Treatment.
    Haider T; Gour V; Pandey V; Kanwar IL; Tiwari R; Vishwakarma M; Bakshi AK; Sarkar A; Yadav R; Soni S; Soni V
    Crit Rev Ther Drug Carrier Syst; 2021; 38(3):75-115. PubMed ID: 34348019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
    Shukla AK; Banerjee M
    High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response.
    Liu Z; Xu W; Xia S; Gu C; Wang X; Wang Q; Zhou J; Wu Y; Cai X; Qu D; Ying T; Xie Y; Lu L; Yuan Z; Jiang S
    Signal Transduct Target Ther; 2020 Nov; 5(1):282. PubMed ID: 33247109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human and novel coronavirus infections in children: a review.
    Rajapakse N; Dixit D
    Paediatr Int Child Health; 2021 Feb; 41(1):36-55. PubMed ID: 32584199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gamma-irradiated SARS-CoV-2 vaccine candidate, OZG-38.61.3, confers protection from SARS-CoV-2 challenge in human ACEII-transgenic mice.
    Turan RD; Tastan C; Dilek Kancagi D; Yurtsever B; Sir Karakus G; Ozer S; Abanuz S; Cakirsoy D; Tumentemur G; Demir S; Seyis U; Kuzay R; Elek M; Kocaoglu ME; Ertop G; Arbak S; Acikel Elmas M; Hemsinlioglu C; Hatirnaz Ng O; Akyoney S; Sahin I; Kayhan CK; Tokat F; Akpinar G; Kasap M; Kocagoz AS; Ozbek U; Telci D; Sahin F; Yalcin K; Ratip S; Ince U; Ovali E
    Sci Rep; 2021 Aug; 11(1):15799. PubMed ID: 34349145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A database resource and online analysis tools for coronaviruses on a historical and global scale.
    Zhu Z; Meng K; Liu G; Meng G
    Database (Oxford); 2021 Aug; 2020():. PubMed ID: 33009914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular evolution and phylogenetic analysis of SARS-CoV-2 and hosts ACE2 protein suggest Malayan pangolin as intermediary host.
    Lopes LR; de Mattos Cardillo G; Paiva PB
    Braz J Microbiol; 2020 Dec; 51(4):1593-1599. PubMed ID: 32592038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Angiotensin-converting enzyme 2: A protective factor in regulating disease virulence of SARS-COV-2.
    Mariappan V; S R R; Balakrishna Pillai A
    IUBMB Life; 2020 Dec; 72(12):2533-2545. PubMed ID: 33031602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evolutionary and structural analysis elucidates mutations on SARS-CoV2 spike protein with altered human ACE2 binding affinity.
    Chakraborty S
    Biochem Biophys Res Commun; 2021 Jan; 534():374-380. PubMed ID: 33272568
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) and Other Coronaviruses: A Genome-wide Comparative Annotation and Analysis.
    Tarique M; Ahmad S; Malik A; Ahmad I; Saeed M; Almatroudi A; Qadah T; Murad MA; Mashraqi M; Alam Q; Al-Saleh Y
    Mol Cell Biochem; 2021 May; 476(5):2203-2217. PubMed ID: 33564990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs.
    Choudhury A; Mukherjee S
    J Med Virol; 2020 Oct; 92(10):2105-2113. PubMed ID: 32383269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular Characterization of SARS-CoV-2.
    Dërmaku-Sopjani M; Sopjani M
    Curr Mol Med; 2021; 21(7):589-595. PubMed ID: 33272175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.